Photoswitchable Drugs
Photoswitchable Drugs - Related Videos
09:12
Dendra2 Photoswitching through the Mammary Imaging Window
0 Views •
Cited by 63 •
2009
Intravital photoswitching and tracking of Dendra2-labeled tumor cells through the Mammary Imaging Window is a technique which allows us to image the metastatic behavior of tumor cells in chosen tumor microenvironments over a timescale of days.
09:33
Determination of the Photoisomerization Quantum Yield of a Hydrazone Photoswitch
0 Views •
2022
Photoisomerization quantum yield is a fundamental photophysical property that should be accurately determined in the investigation of newly developed photoswitches. Here, we describe a set of procedures to measure the photoisomerization quantum yield of a photochromic hydrazone as a model bistable photoswitch.
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
0 Views •
Cited by 4 •
2016
Here we describe a protocol using the web-based drug repurposing hypothesis generation tool: "RE:fine Drugs." This protocol can be modified to a user's preferences at the level of the query type (gene, drug or disease) and/or the range of available advanced options.
07:02
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
0 Views •
Cited by 5 •
2019
A validated computerized battery of neuropsychological and neurophysiological tests is used to study pharmacodynamic effects on the central nervous system of newly developed drugs in early phase development. To demonstrate the test battery, the acute effects of mecamylamine and the reversal of these effects by two agonist drugs are described.
01:30
Drug toxicity: Drug–Drug Interaction
0 Views •
2026
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
FAQs
The photoswitchable group changes molecular configuration after absorbing light, often shifting between cis and trans isomers. This rearrangement changes the compound’s three-dimensional shape and can modify how well it is recognized by a biological target. Because the two configurations may interact differently with that target, illumination can alter signaling or pharmacological activity without changing the compound’s basic chemical identity.
Wavelength determines whether the photoswitchable group absorbs enough light to change configuration and whether illumination can reach the relevant biological location. A wavelength may produce effective switching in a chemical setting but become less useful when tissue penetration is limited. Consequently, wavelength selection directly influences the precision, practicality, and location of the resulting therapeutic response.
Switching efficiency affects how much of the compound reaches the desired configuration after illumination, which influences the strength and reliability of activity control. Compound stability determines whether the molecule retains its chemical and functional properties during use. Together, these factors help establish whether a photoswitchable drug can produce a consistent response rather than an incomplete or short-lived change.
If the two configurations differ in molecular recognition, light can regulate whether a compound interacts effectively with a pathway-associated target. Researchers can therefore examine pathway responses under different illumination conditions and relate those responses to the compound’s configuration. This provides a chemical strategy for probing pharmacological mechanisms with greater temporal and spatial selectivity than uncontrolled activity.
Development requires examining the illumination wavelength, tissue penetration, switching efficiency, and compound stability. These properties determine whether the intended configuration can be generated at the relevant site and maintained long enough to influence biology. Researchers also need to connect the structural change with altered molecular recognition, since switching is useful only if it produces a meaningful change in activity.
By controlling illumination, researchers can compare biological responses associated with different molecular configurations. This enables more precise examination of when a compound affects a signaling pathway and how that activity relates to its chemical structure. In chemistry and drug development, the approach helps connect molecular recognition with pathway behavior, supporting mechanistic studies that would be harder to separate using continuously active compounds.
Light-controlled activity can concentrate a drug’s effect in selected locations or time periods, rather than allowing the same activity to occur uniformly. This precision may help reduce off-target effects, because the active configuration can be generated where and when it is needed. The practical value depends on whether the compound switches efficiently and whether the chosen light can reach the target tissue.
They provide a design framework in which molecular structure, light absorption, configuration, and biological recognition are linked. Chemists can use these relationships to create compounds whose activity is experimentally controllable and to study how structural changes influence signaling. Their relevance extends from investigating pharmacological mechanisms to exploring therapeutic strategies that seek more selective control over drug effects.